Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Dow
Colorcon
McKinsey
Johnson and Johnson
Boehringer Ingelheim

Last Updated: January 26, 2022

DrugPatentWatch Database Preview

Claims for Patent: 9,974,889

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 9,974,889
Title:Gene delivery stent using titanium oxide thin film coating and method for fabricating the same
Abstract: The present invention relates to a gene delivery stent using titanium oxide thin film coating and a method for fabricating the gene delivery stent. The gene delivery stent according to the present invention may be loaded with a drug having anti-inflammatory and anti-thrombotic effects and simultaneously deliver a gene capable of inhibiting proliferation of vascular smooth muscle cells. Accordingly, late thrombosis and metal allergy may be reduced, and vascular restenosis in the stent region may be prevented, thereby making it possible to increase treatment effects of the bare metal stent.
Inventor(s): Kwon; Jin Sook (Gwangju, KR), Ahn; Young Keun (Gwangju, KR), Jeong; Myung Ho (Gwangju, KR), Song; Sun Jung (Gwangju, KR), Cho; Dong Lyun (Gwangju, KR)
Assignee: Chonnam National University Hospital (Gwangju, KR)
Application Number:15/368,825
Patent Claims:1. A gene delivery stent using titanium oxide thin film coating, the gene delivery stent comprising: a titanium oxide thin film obtained by coating a surface of a metal stent with TiO.sub.2-xN.sub.x (0.001.ltoreq.x.ltoreq.1) and modifying the coated surface to introduce a hydroxyl group; a drug layer containing a drug having a functional group bound to a hydroxyl group of the titanium oxide thin film to thereby be adhered onto the titanium oxide thin film; and an oligonucleotide layer containing oligonucleotide bound to the drug to thereby be adhered onto the drug layer, wherein the drug is at least one of abciximab, alpha lipoic acid (ALA), and heparin.

2. The gene delivery stent of claim 1, wherein the oligonucleotide is selected from a group consisting of gDNA, cDNA, pDNA, mRNA, tRNA, rRNA, siRNA, miRNA, and antisense-oligonucleotide.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Merck
Johnson and Johnson
Colorcon
Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.